Last updated: February 13, 2026
Overview
NDC 00093-8107 is a formulation of Varenicline (brand name Chantix), indicated for smoking cessation. The drug has been on the market since its approval by the FDA in 2006. Its market dynamics are influenced by smoking prevalence, regulatory guidance, competitive landscape, manufacturing costs, and reimbursement policies.
Market Size and Penetration
- The U.S. smoking population aged 18 and above is approximately 50 million, with smoking cessation attempts initiated annually at an estimated rate of 43%.
- Chantix holds a significant market share among prescription smoking cessation therapies, competing primarily with bupropion and nicotine replacement therapies (NRT).
- Total prescriptions for Chantix peaked at approximately 2.3 million in 2018 but declined to around 1.65 million in 2021 due to increased generic options and regulatory restrictions.
Key Competitors
- Generic varenicline formulations (post patent expiry)
- Bupropion (Zyban)
- NRT (patches, gum, lozenges)
- Digital therapies and behavioral interventions (emerging segment)
Pricing Trends and Cost Structure
- The original brand Chantix’s average wholesale price (AWP) in 2021 ranged from $350 to $400 per 30-day supply.
- Generic versions launched post patent expiration in 2021, with list prices approximately $180–$250.
- Actual net prices vary based on negotiated discounts, rebates, and insurance coverage.
Pricing Projections
-
Short-term (1–2 years):
As generic market penetration deepens, list prices are projected to decline gradually. Wholesale prices are expected to stabilize around $150–$200 per 30-day supply in the U.S. due to competitive pressures and reimbursement policies.
-
Medium-term (3–5 years):
Assumptions of increased insurance coverage and acceptance of combination therapies could stabilize or slightly increase net prices. Rebate inflation and pharmacy benefit managers’ (PBMs) negotiations will influence final patient costs, likely keeping net prices in a range of $120–$180.
-
Long-term (5+ years):
Market entry of novel smoking cessation drugs (e.g., high-efficacy nicotine vaccines or digital therapeutics) may threaten market share. Price erosion may continue, with projected list prices potentially falling to $100–$150 unless new formulations or indications emerge.
Key Market Drivers
- Regulatory landscape: Increased regulation of smoking products may affect demand for cessation therapies.
- Reimbursement policies: Insurance coverage supports stable demand but constrains pricing.
- Health awareness: Rising tobacco control efforts and health consciousness could sustain demand.
- Patent and exclusivity: Patent expiry has led to a price decrease; future patent protections for new formulations could influence pricing.
Impact of Regulatory and Policy Changes
- FDA initiatives to promote smoking cessation programs could boost demand.
- Medicaid and Medicare coverage decisions heavily influence market access.
- Legislation limiting direct-to-consumer advertising and increasing pharmacy benefit negotiations can suppress net prices.
Market Expansion Opportunities
- Pediatric and adolescent markets, although smaller, represent growth segments.
- Indications for nicotine dependence in other substance use disorders are under exploration for future clinical development.
- International markets remain underpenetrated but face regulatory and pricing hurdles, especially in Europe and Asia.
Summary
The market for NDC 00093-8107 (Varenicline) is experiencing downward pricing pressure due to generics, with net prices stabilized by insurance and reimbursement dynamics. Industry forecasts suggest gradual price declines over the next five years, with potential stabilization or modest increases if new formulations or indications are approved.
Key Takeaways
- Generic availability has reduced list prices; net prices are contingent on negotiated discounts.
- Prescriptions are declining slightly but remain substantial in the smoking cessation market.
- Pricing will likely stabilize around $120–$180 per 30-day supply in the U.S. over the next 3–5 years.
- Market expansion hinges on regulatory, reimbursement, and technological developments.
- Competition from emerging therapies could further influence pricing and market share.
FAQs
-
What factors most influence the price of NDC 00093-8107?
Patent expiration, generic competition, insurance reimbursement policies, and pharmacy negotiations primarily influence pricing.
-
How does generic market entry affect net revenue?
Generic entry tends to reduce list prices; however, net revenue depends on negotiated rebates and discounts with payers.
-
Are there upcoming regulatory changes that could impact demand?
The FDA may implement policies promoting smoking cessation, potentially increasing demand, especially if new indications or formulations are approved.
-
What potential new markets could affect long-term demand?
Digital therapies, combination treatments, and indications for other substance use disorders are emerging markets.
-
How do international markets compare in pricing and access?
Many countries face regulatory and price controls that suppress prices; the U.S. remains the largest market with the highest per-unit costs.
References
[1] IQVIA. "IQVIA Prescription Data," 2022.
[2] Centers for Disease Control and Prevention. "Smoking & Tobacco Use," 2021.
[3] U.S. Food and Drug Administration. "Approval of Varenicline," 2006.
[4] GoodRx. "Average Retail Prices for Chantix," 2022.
[5] EvaluatePharma. "Pharmaceutical Market Trends," 2022.
